ClinicalTrials.gg
CompletedNCT05424549Updated Jan 15, 2025Results posted

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Dry Eye Syndromes, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2022, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
9th of 11
63 · median 158
Started
2022
the only one that year
Phase 2
5 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 8th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

Keywords

  • dry eye disease
  • reproxalap
  • Aldeyra
  • ADX-102
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eighteen (18) to 70 years of age at the time of screening (either gender and any race)
  2. Ability to provide written
  3. Reported history of dry eye for at least 6 months prior to screening
  4. Reported history of the use of eye drops for dry eye disease between 2 weeks to 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), active ocular inflammation, or history of inflammatory disease (that, in the opinion of the Investigator, could interfere with study conduct or assessments) at screening
  2. Contact lens use within 7 days of screening or anticipate using contact lenses during the trial
  3. Systemic or other immunomodulatory therapy (not including inhaled corticosteroids) within 60 days of screening, or any planned immunomodulatory therapy throughout the study period
  4. Women of (WOCBP) who are pregnant and nursing
  5. If participant is of childbearing potential (female or male), unwillingness to use an acceptable means of .
  6. Known allergy and/or sensitivity to reproxalap or the drug product vehicle
  7. A condition that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the trial
  8. Inability or unwillingness to follow instructions, including participation in all study assessments/procedures and visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%)

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Placebo comparator
    Vehicle Ophthalmic Solution

    Drug: Vehicle Ophthalmic Solution

Interventions

  • Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days

  • DrugVehicle Ophthalmic Solution

    Vehicle Ophthalmic Solution dosed six times over two consecutive days

06

What researchers measure

Primary outcomes

  1. Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber

    Change from baseline comparison of reproxalap to vehicle for conjunctival redness assessed on a 0 to 4 scale (0 = none, 4 = extremely severe). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.

    Time frame: The efficacy assessment period was during a 90-minute dry eye chamber; baseline was pre-dose #1 for each treatment period.

  2. Schirmer Test Mean Change From Baseline

    Change from baseline comparison of reproxalap to vehicle for schirmer test on a millimeter line (0 = none, 35 = maximum). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.

    Time frame: The efficacy assessment period was assessed on the first day of two consecutive dosing days for both crossover periods; baseline was pre-dose #1 for each treatment period.

07

Results

Posted Jan 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneReproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)
Started3231
Completed2928
Not completed33

Outcome measures

PrimaryConjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber

Change from baseline comparison of reproxalap to vehicle for conjunctival redness assessed on a 0 to 4 scale (0 = none, 4 = extremely severe). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.

Time frame:
The efficacy assessment period was during a 90-minute dry eye chamber; baseline was pre-dose #1 for each treatment period.
Reported as:
Least squares mean · score on a scale
Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber
score on a scaleReproxalap (0.25%)Vehicle
Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber0.33 (0.23 to 0.43)0.44 (0.34 to 0.54)
PrimarySchirmer Test Mean Change From Baseline

Change from baseline comparison of reproxalap to vehicle for schirmer test on a millimeter line (0 = none, 35 = maximum). The least squares mean (95% confidence interval) was derived from mixed model repeated measure for change from baseline included baseline as a covariate, and treatment, period, sequence, and time point as factors.

Time frame:
The efficacy assessment period was assessed on the first day of two consecutive dosing days for both crossover periods; baseline was pre-dose #1 for each treatment period.
Reported as:
Least squares mean · score on a scale
Schirmer Test Mean Change From Baseline
score on a scaleReproxalap (0.25%)Vehicle
Schirmer Test Mean Change From Baseline-0.06 (-1.82 to 1.70)-2.54 (-4.22 to -0.86)

Adverse events

Collected over Two days for each intervention. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap (0.25%)0/61 (0%)0/61 (0%)56/61 (91.8%)
Vehicle0/60 (0%)0/60 (0%)2/60 (3.3%)
Most frequent other events
Most frequent other events
EventReproxalap (0.25%)Vehicle
General disorders and administration site conditionsGeneral disorders56/612/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
<=18 years000
Between 18 and 65 years302959
>=65 years224
Age, Continuous
Age, Continuous(years)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
Mean47.0 ± 13.1251.2 ± 12.1449.1 ± 12.72
Sex: Female, Male
Sex: Female, Male(Participants)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
Female172441
Male15722
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
American Indian or Alaska Native000
Asian6612
Native Hawaiian or Other Pacific Islander000
Black or African American213
White241943
More than one race055
Unknown or Not Reported000
Intraocular Pressure (right eye)
Intraocular Pressure (right eye)(mmHg)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
Mean11.6 ± 2.0812.0 ± 2.7611.8 ± 2.42
Intraocular Pressure (left eye)
Intraocular Pressure (left eye)(mmHg)Reproxalap (0.25%) First, Then VehicleVehicle First, Then Reproxalap (0.25%)Total
Mean11.7 ± 1.9711.6 ± 2.6111.6 ± 2.29
08

Study locations

1 site
  • Cliantha Research
    Mississauga, Ontario L4W 1A4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2022, 2 months.

Results were first posted in Jan 2025, 2 years 8 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2022
First posted
Jun 21, 2022
StartActual
Mar 9, 2022
Primary completionActual
May 9, 2022
CompletionActual
May 9, 2022
Results first posted
Jan 15, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05424549
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Mar 9, 2022
Primary completion
May 9, 2022
Completion
May 9, 2022
Results posted
Jan 15, 2025
Last update
Jan 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion